Oncology & Cancer
Low-dose sorafenib may improve therapy for head and neck cancer
Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers ...
May 16, 2011
0
0
